COST-CONSEQUENCE OF CLADRIBINE TABLETS FOR THE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE UK

被引：0
作者：
Miller, B. [1 ]
Russel-Szymczyk, M. [2 ]
Jensen, I. S. [3 ]
Shah, A. [1 ]
Alexopoulos, S. T. [4 ]
Herbert, A. [4 ]
McLean, T. [4 ]
Tundia, N. [5 ]
机构：
[1] Precis Hlth Econ & Outcomes Res, Grafton, MA USA
[2] Merck Sp Zoo, Affiliate Merck KGaA, Warsaw, Poland
[3] Precis Hlth Econ & Outcomes Res, Boston, MA USA
[4] Merck Serono Ltd, Affiliate Merck KGaA, Feltham, England
[5] EMD Serono Res & Dev Inst Inc, Affiliate Merck KGaA, Billerica, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE658
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 50 条
  • [21] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands (vol 17, pg 857, 2019)
    Michels, Renee Else
    De Francesco, Maria
    Mahajan, Koshu
    Hengstman, Gerald J. D.
    Schiffers, Krijn M. H.
    Budhia, Sangeeta
    Harty, Gerard
    Krol, Marieke
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2020, 18 (01) : 141 - 141
  • [22] Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England
    Maruszczak, Maciej J.
    Montgomery, Stephen M.
    Griffiths, Matthew J. S.
    Bergvall, Niklas
    Adlard, Nicholas
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (11) : 874 - 885
  • [23] REGIONAL EFFICACY OF NATALIZUMAB TREATMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
    Doshi, Anisha
    Voysey, Zanna
    Bunting, Eva
    Malik, Muzaffar
    Rashid, Waqar
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11)
  • [24] Effect of cladribine tablets on brain atrophy rates in patients with relapsing-remitting multiple sclerosis (RRMS): exploratory analysis of the CLARITY study
    de Stefano, N.
    Giorgio, A.
    Battaglini, M.
    Giovannoni, G.
    Hicking, C.
    Dangond, F.
    Sormani, M. P.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 532 - 532
  • [25] COST-EFFECTIVENESS OF CLADRIBINE TABLETS IN THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL
    Pinheiro, B. A.
    Guerreiro, R.
    Costa, J.
    Silva Miguel, L.
    [J]. VALUE IN HEALTH, 2018, 21 : S339 - S339
  • [26] Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis
    Rosa Cortese
    Giovanna Testa
    Francesco Assogna
    Nicola De Stefano
    [J]. CNS Drugs, 2024, 38 : 267 - 279
  • [27] Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis
    Cortese, Rosa
    Testa, Giovanna
    Assogna, Francesco
    De Stefano, Nicola
    [J]. CNS DRUGS, 2024, 38 (04) : 303 - 314
  • [28] Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets
    Signori, Alessio
    Ponzano, Marta
    Alexandri, Nektaria
    Giovannoni, Gavin
    Sormani, Maria Pia
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (07) : 2144 - 2147
  • [29] Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis (vol 25, pg 239, 2011)
    Muir, Victoria J.
    Plosker, Greg L.
    [J]. CNS DRUGS, 2020, 34 (04) : 447 - 447
  • [30] Cladribine tablets. Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods
    Meuth, S. G.
    Ruck, T.
    Aktas, O.
    Hartung, H-P
    [J]. NERVENARZT, 2018, 89 (08): : 895 - 907
12345